Skip to main content
SpringerPlus

Table 1 Patient characteristics (n = 40)

From: Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade

 

Zoledronic acid

Control

P value

No. of patients treated

19

21

 

Age (years)

72.9 ± 4.8

73.4 ± 5.2

0.75

Strategy of ADT

   

 First-line therapy

12

16

0.37

 Salvage therapy

7

5

 

T-stage

   

 T1c

1

0

0.19

 T2

5

2

 

 T3

12

19

 

 T4

1

0

 

N-stage

   

 N0

15

18

0.59

 N1

4

3

 

Gleason score

   

 ≤6

2

3

0.25

 7

5

9

 

 ≥8

12

9

 

Pretreatment PSA (ng/ml)

76 ± 159

37 ± 72

0.33

BMD (g/cm2)

1.235 ± 0.21

1.182 ± 0.22

0.45

T-score

0.55 ± 2.04

0.05 ± 1.91

0.46

Biomarker of bone turnover

 Serum NTX (nmolBCE/L)

15.27 ± 4.86

16.13 ± 5.30

0.62

 Serum ICTP (ng/ml)

4.02 ± 1.71

4.40 ± 1.65

0.48

 Serum BAP (U/L)

11.57 ± 2.85

13.35 ± 4.29

0.13

  1. ADT, androgen deprivation therapy; PSA, prostate-specific antigen; BMD, bone mineral density; NTX, cross-linked N-telopeptide of type I collagen; ICTP, C-telopeptide of type I collagen; BAP, bone-specific alkaline phosphatse.
Back to article page